FDA Approval Round Up: Keytruda, Opdivo Add Claims
Cancer supplements took center stage for US FDA this week, but OptiNose Inc.'s corticosteroid Xhance also took a bow.
You may also be interested in...
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.
Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.
Keeping Track: A Burst Of Breakthroughs, A Priority Review For Keytruda, And Some Supplemental Submissions
The latest drug development news and highlights from our US FDA Performance Tracker.